Melanoma Clinical Trial
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma. This study will explore the safety, tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also receiving pembrolizumab.
Key Inclusion Criteria:
Stage IIIB, IIIC or IV melanoma
Previously untreated and eligible for pembrolizumab treatment (prior treatment with BRAF and MEK inhibitors permitted) 3) Adequate blood, liver and kidney function 4) Consent to undergo tumor biopsies during the study
Uveal or ocular malignant melanoma
History of hematologic or primary solid tumor malignancy with the exception of patients in remission for at least 5 years, as judged by the investigator are allowed
Prior systemic treatment for unresectable or metastatic melanoma. Exception: Prior treatment with BRAF and MEK inhibitors permitted. A washout period of at least 3-half-lives (median terminal half-life) prior to the first dose of trial treatment must have elapsed.
Prior therapy with an anti-CTLA4, anti-PD-1, anti-PD-L1, anti-PD-L2 agent or oncolytic virus.
Known hypersensitivity to GM-CSF
Women who are breastfeeding, pregnant or expect to be pregnant during the study through 6 months after the last dose
Men who plan to become a father during the study through 4 months after the last dose of study medication
Known history of, or any evidence of active, non-infectious pneumonitis
History of cardiac disease
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Santa Monica California, 90404, United States
Iowa City Iowa, 52242, United States
Easton Pennsylvania, 18045, United States
Salt Lake City Utah, 84112, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.